Multiple Autoimmune Complications After a Single Dose of Pembrolizumab

Pembrolizumab, a monoclonal antibody that inhibits programmed cell death protein-1 (PD-1), is an important treatment for various malignancies. Unfortunately, it has also been associated with a wide array of immune-related adverse events. We present a unique case of a patient who received a single do...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahdi, Hardeep S, Abdulmujeeb, Sufyan, Nabrinsky, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079282/
https://www.ncbi.nlm.nih.gov/pubmed/37033516
http://dx.doi.org/10.7759/cureus.35871
Descripción
Sumario:Pembrolizumab, a monoclonal antibody that inhibits programmed cell death protein-1 (PD-1), is an important treatment for various malignancies. Unfortunately, it has also been associated with a wide array of immune-related adverse events. We present a unique case of a patient who received a single dose of pembrolizumab and subsequently developed multiple immune-mediated complications, including dermatitis, hepatitis, myositis, myocarditis, and myasthenia gravis.

Ejemplares similares